abstract |
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic acid (20:5; EPA), or esters thereof, and (iii) choline, or salts or esters thereof, in the manufacture of a product for therapeutically improving language development and reducing language skills impairment in children with suspected or confirmed cerebral palsy, or children at risk thereof. |